# Y. Wang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/y-wang-3/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 1 |
| i10-index | 0 |
| Last Known Institution | Ministry of Education |
| OpenAlex ID | https://openalex.org/A5061686350 |
| Works | 3 |

## Researcher papers

- [EP.12D.03 Characterization of HER2Alterations in 23,321 NSCLC Cases and Real-World Therapeutic Pattern in Chinese HER2-Mutant NSCLC the CHAPTER Study](https://scholariq.org/papers/ep-12d-03-characterization-of-her2alterations-in-23-321-nsclc-cases-and-real/)
- [32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI](https://scholariq.org/papers/32p-atezolizumab-plus-albumin-paclitaxel-based-regimens-is-an-optional-treatment/)
- [Age-Stratified Transcriptomic Profiling Reveals Biologically Distinct Molecular Phenotypes Across Pediatric, Adolescent, and Adult Osteosarcoma](https://scholariq.org/papers/age-stratified-transcriptomic-profiling-reveals-biologically-distinct-molecular/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Bone Tumor Diagnosis and Treatments](https://scholariq.org/topics/bone-tumor-diagnosis-and-treatments/)

## Researcher university

- [Ministry of Education](https://scholariq.org/institutions/ministry-of-education-14/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.